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Optimal management of central nervous system (CNS) infiltration is a key remaining 
challenge in delivering precision therapy for childhood acute lymphoblastic leukaemia 
(ALL)1. Most CNS relapses occur in children without high-risk features and minimal residual 
disease does not reliably predict CNS relapse.1, 2 Consequently, all children receive intensive 
CNS-directed therapy, which is potentially toxic to the developing brain3.  The nature of cells 
infiltrating the CNS is a subject of much debate with some believing that a subset of cells 
selectively traffic to the CNS compartment whilst others believe that all ALL cells are capable 
of entering the CNS. The majority of mechanistic work addressing this question has been 
performed in patient-derived xenograft (PDX) models. Here, we report the first description of 
the clonal architecture of CNS and paired bone marrow (BM) compartments in patients with 
ALL, using high throughput sequencing (HTS) of primary patient BM and cerebrospinal fluid 
(CSF) samples taken at diagnosis and relapse. This addresses a significant gap in our 
understanding of how faithfully PDX models recapitulate clonal architecture in patients. Our 
data support our hypothesis that CNS and BM ALL share common characteristics and after 
their development in the BM almost all B-cell precursor ALL clones are capable of 
disseminating to the CNS. In addition, they suggest that in most cases CNS and 
accompanying BM relapses are not intrinsically different biologically, often arising from the 
same subclones at the two sites.  
 
Tailored CNS-directed therapy requires improved understanding of mechanisms of CNS 
relapse and development of more sensitive assays to track CNS response during therapy. 
CNS leukaemia is usually detected by CSF cytology. CSF flow cytometry or PCR are more 
sensitive1, 4, 5, but increased detection at diagnosis has not improved prediction of CNS 
relapse, possibly because it measures disease load at baseline rather than response to 
therapy6. PDX models suggest that up to 80% of diagnostic BM samples can engraft in the 
CNS7 and cellular bar-coding experiments show the clonal composition within murine CNS 
and BM compartments are similar7. This suggests the ability to enter the CNS-compartment 
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is a generic property of ALL. However, these results contrast with other studies indicating 
that CNS leukaemic blasts may selectively express genes associated with trafficking.2, 8, 9 
Interpretation of PDX data has caveats, since CNS infiltration is measured without selective 
pressures of CNS-directed therapy or immunosurveillance and species differences may 
make microenvironments more or less permissive for expansion.1 
New techniques using HTS of immunoglobulin gene rearrangements allow detailed 
interrogation of ALL sub-clonal composition within individual patients.10 Unlike conventional 
PCR, using allele-specific primers, HTS is able to visualise all gene rearrangements 
simultaneously and therefore uncover the extent of initial clonal diversity and the influence of 
selective pressures over time11. Here we use HTS to investigate clonal relationships 
between leukaemic cells directly isolated from patients CSF and BM in childhood ALL. This 
provides an important test of the validity of PDX models and insights into CNS and BM 
clonal selection during therapy.  
Following ethical approval (REC 13/LO/1262), BM and CSF were obtained from patients with 
CNS involvement. Clinical details and samples available for analysis are given in Table 1. 
Samples were processed as previously described.11 Briefly, DNA was amplified by multiplex-
PCR of rearranged VDJ (Variable, Diverse, Joining) segments of the immunoglobin heavy 
chain (IGH) genes, which encode the hypervariable CDR3 domain and sequenced on a 
MiSeq (Illumina, San Diego, CA). Due to sample constraints IGH was chosen as this was the 
dominant clone by screening at diagnosis in all the patients and was used as MRD marker. 
Further experimental details are described in Supplementary Methods and Supplementary 
Table 1. Rearrangements were annotated with reference to ImMunoGeneTics germline 
sequences12 using Vidjil.13 The ultra-sensitivity of HTS detecting VDJ rearrangements comes 
with the problem of distinguishing leukaemia-specific from normal-background repertoire. 
The frequency of most common IGH gene rearrangements from BM aspirates of healthy 
individuals has been shown to average 0.04 - 0.08%.14 For this study, a neoplastic clone 
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was defined as rearrangements with frequencies >1% in an individual sample, or where the 
identical rearrangement (at level >1%) is seen in a paired sample at any level.  
We analysed twelve consecutive patients with B-cell precursor ALL and CNS involvement. 
High and low-risk patients were represented and four cases had a clinically isolated CNS 
relapse (Table 1). Criteria for CNS relapse was defined as ≥ 5 white blood cells per µl of 
CSF with morphological evidence of lymphoblasts. A combined BM/CNS relapse was 
defined as presence of CNS disease with ≥ 5% blasts in a concomitant BM aspirate. One 
patient had CNS involvement at diagnosis, in eight patients, material was available from 
diagnosis and relapse, and three patients had samples from CNS relapse but no original 
diagnostic material. Combined relapses are shown in Figure 1 and isolated CNS relapses in 
Figure 2, detailed information on the identity and percentages of clones in different 
compartments is given in Supplementary table 2. 
Firstly, we examined CNS and BM clones in the patient with overt CNS infiltration at original 
diagnosis (CNS004, Figure 1A). The CNS and BM compartments share identical dominant 
clones albeit with reversed proportions between compartments. Next, we compared BM and 
CSF at the time of combined relapse, these results fell into two distinct patterns (Figure 1G 
and Figure 1H). In the majority, (5/7: CNS001, CNS003, CNS007, CNS008, CNS009) 
(Figure 1B-F and Supplementary table 2), BM and CSF clonal composition are remarkably 
similar at the time of relapse, in terms of both the extent of clonal diversity and the dominant 
clones. In the remaining 2 patients (CNS002, CNS006, Figure 1I - J) there was evidence for 
some separate clonal evolution at the two sites although notably, all CNS clones are 
detectable in the BM albeit sometimes at very low frequencies. 
We then examined the 4 patients with apparently isolated CNS relapse (Figure 2 A-D). In 
cases, CNS010, CNS011 and CNS012 examination of the paired (apparently uninvolved) 
BM at the time of relapse using the HTS assay, identified low-level BM involvement with all 
CNS clones also detected in the BM compartment – albeit at very low frequencies. The 
fourth patient (CNS005) initially had an isolated CNS relapse at 72 months (CSF sample 
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analysed), then achieved remission before combined relapse at 100 months (BM sample 
analysed). Again the 2 dominant clones at CNS relapse were the dominant clones at BM 
relapse. Therefore, these cases of clinical CNS involvement with subclinical or later BM 
relapse also fit into pattern 1 (Figure 1G). In the 7 patients with diagnostic BM available 
(CNS001 (Figure 1B), CNS002 (Figure 1I), CNS003 (Figure 1C), CNS005 (Figure 2A), 
CNS006 (Figure 1J), CNS010 (Figure 2B) and CNS012 (Figure 2D) three patients showed 
persistence of the original dominant clone, two showed falling levels of the dominant 
diagnostic clone with a rise in minor subclones whilst the other two showed loss of the 
dominant clone and selection of minor subclones at relapse. This rise and fall of subclones 
between diagnosis and relapse is a phenomenon widely reported in the literature.15  
These data represent the first description of the clonal architecture of CNS and paired BM 
compartments in patients with ALL and extends our understanding of mechanisms of CNS 
leukaemia. However, several limitations should be noted when interpreting our results. 
Patient numbers are small due to the difficulty of obtaining these rare samples. Also, in order 
to complete the full clonal picture, other immunoglobulin and T-cell receptor gene loci could 
be assessed if DNA quantity allowed. Results from the patient with CNS disease at 
diagnosis are consistent with our hypothesis that ALL cells freely traffic to the CNS with no 
evidence for selection of “CNS-tropic” subclones. A similar situation is seen at relapse, with 
9 out of 11 patients sharing subclones between BM and CNS compartments. This supports 
our previous PDX work showing the polyclonal nature of CNS-infiltrating cells which share 
similar clonal architecture with BM and spleen9. Interestingly, although most patients showed 
emergence of minor subclones during treatment, they did not differ between CNS and BM. 
This is perhaps surprising as selective pressures (chemotherapy exposure, immune 
surveillance and nutrient availability) vary between the two sites. Two possible explanations 
can be postulated. Firstly, relapse clones emerge at one site and then freely traffic to the 
other site prior to overt clinical relapse (akin to free trafficking seen at original diagnosis). 
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This mechanism is further supported by our data showing clones identified in the CNS at 
apparently isolated relapse are also detectable in the corresponding BM at low frequency.  
Alternatively, relapse mechanisms are cell-intrinsic with certain subclones predetermined to 
be biologically fitter (presumably due to additional mutations), irrespective of their local 
microenvironment. In contrast, 2 of 11 patients with CNS relapse, had some separate clonal 
evolution between BM and CNS, although many shared clones were also seen. In these 
cases, varying selective pressures or local acquisition of advantageous mutations may 
cause differential expansion in the two compartments. Using the more sensitive HTS assay, 
BM disease was detectable in all patients with apparently isolated CNS relapse, further 
evidence that BM infiltration is present at some level even in apparently isolated CNS 
relapse.1, 5  
Overall, our data support the hypothesis that CNS and BM ALL share common 
characteristics and that almost all clones can disseminate to the CNS. In addition, they 
suggest that CNS and BM relapses are not intrinsically biologically different, often arising 
from the same subclones at the two sites or freely trafficking between compartments at the 
time of relapse.  Thus we provide underpinning science to the long-held belief, derived from 
clinical observations, that CNS and BM relapses are “competing events” rather than distinct 
clinical entities i.e. increased CNS-directed therapy reduces overt CNS relapses but results 
in late BM relapses and vice versa5. These observations support use of at least some CNS-
directed therapy for ALL irrespective of CSF findings at diagnosis. Ultra-sensitive techniques 
such as HTS may allow dynamic tracking of CNS and BM response to treatment permitting 
more precise risk-adapted therapy tailored to the risks of BM and CNS relapse.  
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Table 1. Patient characteristics of ALL samples with CNS involvement 
CNS-1 no blasts in CSF; CNS-2 atraumatic < 5 blast/µl; CNS-3 > 5 blast/ µl; CCR continued complete remission; BM bone marrow; CSF cerebrospinal 
fluid; • sample available;   no sample available; NA not applicable; *on treatment relapse; † BM samples at time of combined relapse. 
Patient Age at 
diagnosis 
(years) 
Highest 
WCC 
(x10
9
/l) 
CNS at 
diagnosis 
Cytogenetics Treatment 
protocol 
End of  
induction 
MRD 
Time to 
relapse 
(months) 
Relapse Samples available 
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CNS001 3 2.6 CNS-1 CDKN2A deletion 
 
UKALL2011 Low risk 17 * Combined  
• • • 
CNS002 4 6.7 CNS-1 ETV6-RUNX1 UKALL2011 Risk 34 Combined 
 
• • • 
CNS003 1 263.2 CNS-1 KMT2A [t(9;11)] UKALL2011 Risk 3* Combined 
 
• • • 
CNS004 3 7.5 CNS-3 High hyperdiploid UKALL2011 Risk CCR None 
 
• • NA 
CNS005 4 12.7 CNS-1 High hyperdiploid UKALL2003 Low Risk 72 Isolated CNS then 
combined 
• • •† 
CNS006 1 207.4 CNS-1 KMT2A[t(9;11)] UKALL2011 Risk 6* Combined 
 
• • • 
CNS007 1 296 CNS-2 KMT2A [t4;11)] UKALL2011 Risk 18* Combined 
 
9 • • 
CNS008 2 240.0 CNS-1 ETV6-RUNX1 UKALL2011 Risk 48  Combined 
 
9 • • 
CNS009 5 18.1 CNS-1 ETV6-RUNX1 UKALL2011 Risk 45 Combined 
 
9 • • 
CNS010 4 
 
3.5 CNS-1 ETV6-RUNX1 UKALL2003 Low risk 74  Isolated CNS 
• • • 
CNS011 3 
 
1.5 CNS-1 CDKN2A deletion UKALL2011 Risk 22* Isolated CNS 
9 • • 
CNS012 2 
 
7.1 CNS-1 High hyperdiploid UKALL2011 Low risk 30* Isolated CNS 
• • • 
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Figure legends 
Figure 1. Combined relapses, CNS disease at presentation and schematic 
presentation of the types of relapse seen. (A) CNS004. CNS involvement at diagnosis, 
showing both compartments share the two dominant clones albeit at reversed frequencies. 
(B) CNS001. The dominant diagnostic BM clone is IGHV4-34*01/IGHD2-2*01/IGHJ5*02 at 
85%, only present at 0.002% in BM relapse and undetectable at CNS relapse. The dominant 
clone in BM and CNS relapse samples is IGHV6-1*01/IGHJ5*02 at 78% and 88% 
respectively (in original diagnostic BM only 4%). (C) CNS003. The dominant clone in all 
three samples is IGHV1-46*01/IGHD3-3*01/IGHJ4*02 at 91%, 50% and 94% in diagnosis 
BM, BM relapse and CNS relapse respectively. (D) CNS007. Identical dominant clone 
IGHD6-13*01/IGHJ4*02 37% and 45% respectively in the BM relapse and CNS relapse 
samples. There is a smaller clone (15%) IGHD2-2*02/IGHJ4*02 in BM, not detectable in 
CNS sample. In contrast, there is 11% IGHD2-2*02/IGHJ4*02 in CNS relapse not detectable 
in the BM relapse sample. (E) CNS008. Identical dominant clone IGHV3-30-3*01/IGHD3-
9*01/IGHJ6*03 at 95% and 64% in BM relapse and CNS relapse respectively. (F) CNS009. 
Identical dominant clones IGHV1-46*01/IGHD5-12*01/IGHJ4*02 at 34% and 48%, and 
IGHV3-71*02/IGHD6-6*01/IGHJ4*02 at 31% and 40% in BM and CNS respectively. (G and 
H) Schematic presentation of the two patterns of relapse seen. Left panel (“Pattern 1”) 
shows the same ALL clones in BM and CNS at relapse with no evidence for selection of 
“CNS-tropic” subclones, this could be due to relapse occurring at one or other site and then 
free trafficking between the CNS and BM, or due to the same clones surviving treatment 
independently at the two sites. The right panel (“Pattern 2”) shows the alternative pattern, 
where there is evidence for some separate clonal evolution at the two sites although many 
clones are also present in both compartments. (I) CNS002. Dominant diagnostic BM clones 
are 36% IGHV1-69*06/IGHD5-12*01/IGHJ4*02, 11% IGHV3-72*01/IGHD2-8*02/IGHJ4*02 
and 10% IGHV1-18*01/IGHD2-2*02/IGHJ6*02. The dominant clone in the relapse BM 
sample is also IGHV1-69*06/IGHD5-12*01/IGHJ4*02 at 45%, however, this is only present 
at 5% in the CNS relapse sample. The second dominant clone in the relapse BM sample is 
IGHV3-74*01/IGHD5-12*01/IGHJ4*02 at 34% is only present at 0.1% in diagnostic BM and 
0.1% in CNS relapse. CNS relapse dominant clone is IGHV3-74*01/IGHD7-27*01/IGHJ6*02 
at 43% which is absent in the original diagnostic BM and only 0.6% in BM relapse.  The 
second dominant clone in the CNS is IGHV3-74*01/IGHJ6*02 14% (which is again absent in 
the original diagnostic and only 0.06% in BM relapse.  The dominant clones in the CNS 
(IGHV3-74*01/IGHD7-27*01/IGHJ6*02 and IGHV3-74*01/IGHJ6*02) share the same IGHV 
and IGHJ gene usage but the CDR3 regions are different and unrelated– shown in 
Supplementary Figure 1. (J) CNS006. Shows change in clones from diagnosis through to 
combined BM and CNS relapse. Dominant diagnostic BM clone is IGHV6-1*01/IGHD3-
10*01/IGHJ6*02 26% (this is very low level at 0.9% in relapse BM and undetectable in CNS 
relapse). IGHV3-30-3*01/IGHJ4*02 was only 2% at diagnosis but 10% in relapse BM and 
1% in CNS relapse. Dominant clone in the relapse BM IGHV3-11*06/IGHJ4*02 at 41% was 
not detectable in the diagnostic sample or in CNS relapse samples. Other dominant relapse 
BM clones were 11% IGHV1-3*01/IGHD2-8*01/IGHJ4*02 (2% in original diagnostic BM and 
1% in CNS relapse), 10% IGHV3-30-3*01/IGHD2-8*01/IGHJ4*02 (2% in original diagnostic 
BM and 1% in CNS relapse). The dominant clone in CNS relapse was  IGHV6-1*01/IGHD2-
8*01/IGHJ4*02 at 26% was only low level in original diagnostic and relapse BM samples at 
0.4% and 0.5% respectively; The other dominant clones in the CNS were 21% IGHV3-
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30*18/IGHJ4*02 (0.01% and in original diagnostic and relapse BM respectively) and 16% 
IGHV7-4-1*01/IGHJ6*02 (0.02% in original diagnostic and 0.1% in relapse BM).   
Figure 2. Isolated CNS relapses. (A) CNS005. Dominant diagnostic BM clone is IGHV1-
8*01/IGHD2-2*02/IGHJ6*03 at 55%. At relapse, the dominant clones are IGHV3-23/IGHD2-
2*02/IGHJ6*03 and IGHV1-2*04/IGHD3-22*01/IGHJ6*03 respectively in BM 40% and 48%, 
and CNS 39% and 45%. In original diagnostic BM IGHV3-23/IGHD2-2*02/IGHJ6*03 
represents 0.005% and IGHV1-2*04/IGHD3-22*01/IGHJ6*03 represents 0.01%. The 
dominant clone in the diagnostic BM IGHV1-8*01/IGHD2-2*02/IGHJ6*03 55% is not 
detectable at relapse, but on further analysis, this has been V-V replaced whereby IGHV1-
8*01 is replaced to create the IGHV3-23/IGHD2-2*02/IGHJ6*03 clone at relapse 
(Supplementary Figure 2). The presence of the IGHV3-23/IGHD2-2*02/IGHJ6*03 clone in 
the diagnostic BM albeit at very low level also demonstrates there is V-V replacement at 
diagnosis. (B) CNS010. Dominant clone in diagnostic BM is IGHV3-15*01/IGHD6-
19*01/IGHJ6*02 at 31%, there are three other subclones, 24% IGHV4-59*01/IGHD3-
10*01/IGHJH3*02, 12% IGHV3-33*01/IGHD6-6*01/IGHJ2*01 and 6% IGHV1-
46*01/IGHJ4*02. At time of CNS relapse the dominant clone is also IGHV3-15*01/IGHD6-
19*01/IGHJ6*02 at 41%, however, the other three dominant clones present in diagnostic BM 
are undetectable in the CSF sample. The other dominant clone in the CNS relapse is 
IGHV4-59*01/ IGHD3-10*01/IGHJH3*02 at 46% which is only present at a level 0.0001% in 
diagnostic BM. The BM in morphological remission at time of CNS relapse shows very low 
level of the CNS dominant clone IGHV4-34*01/ IGHJ2*01 at a level 0.12% and the original 
diagnostic BM clone IGHV3-15*01/IGHD6-19*01/IGHJ6*02 0.05%. (C) CNS011. Dominant 
clones in CSF at CNS relapse IGHV4-34/IGHD3-9*01/IGHJ6*02 at 54% and IGHV3-
33*01/IGHD3-10*02/IGHJ3*02 at 34%. These clones are detected at low level in BM at time 
of CNS relapse 0.54% and 0.33% respectively, with no additional dominant clones detected. 
(D) CNS012. Dominant clones in diagnostic BM are IGHV1-2*04/IGHD7-27*01/IGHJ2*01 
and IGHV7-4-1*02/IGHD5-12*01/IGHJ6*02 at 32.4% and 31.7% respectively. In the CNS 
relapse CSF sample, the same two dominant clones are present at comparable levels. The 
BM at time of CNS relapse was morphologically negative, however, there was low-level 
positivity for both clones by both real-time PCR and HTS. 
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SUPPLEMENTARY MATERIAL
Supplementary Methods
Processing of samples
For BM samples, the total mononuclear cell fraction was isolated following centrifugation on
Ficoll-Hypaque. CSF cells were pelleted by centrifugation and directly DNA directly
extracted. DNA was extracted according to standardised protocols using QIAamp DNA Mini
or Mirco Kit (Qiagen). DNA concentration was estimated using spectrophotometry
(Nanodrop, Thermo Scientific) and then accurately quantitated by RQ-PCR using albumin as
a control/reference gene. DNA and approximate cells numbers (based on 6.6 pg DNA per
cell) analysed are show in supplementary table 1.
High throughput sequencing
Paired patient samples were run on separate MiSeq lanes, as well as other measures
employed to prevent cross contamination.1 We used a single-end 250-300 read from J to V
to ensure optimal quality over the CDR3-encoding region. Indexing reads were performed to
identify the 8 base pair dual indices sequences at both ends of the amplicons.
Supplementary references
1. Bartram J, Mountjoy E, Brooks T, et al. Accurate Sample Assignment in a
Multiplexed, Ultrasensitive, High-Throughput Sequencing Assay for Minimal Residual
Disease. J Mol Diagn. 2016;18(4):494-506.
Patient DNA samples input
BM
diagnosis
BM
relapse
CSF
relapse
CNS001 500 ng
75000 cells
500 ng
75000 cells
85 ng
12300 cells
CNS002 500 ng
75000 cells
500 ng
75000 cells
100 ng
15000 cells
CNS003 500 ng
75000 cells
500 ng
75000 cells
100 ng
15000 cells
CNS004 500 ng
75000 cells NA
*50 ng
7500 cells
CNS005 500 ng
75000 cells
500 ng
75000 cells
100 ng
15000 cells
CNS006 500 ng
75000 cells
500 ng
75000 cells
100 ng
15000 cells
CNS007 ◌ 500 ng75000 cells
40 ng
6000 cells
CNS008 ◌ 500 ng75000 cells
50 ng
7500 cells
CNS009 ◌ 500 ng75000 cells
70 ng
11000 cells
CNS010 500 ng
75000 cells
6 ug
1000000 cells
100 ng
15000 cells
CNS011 ◌ 500 ng75000 cells
100 ng
15000 cells
CNS012 500 ng
75000 cells
1 ug
150000
100 ng
15000 cells
Supplementary table 1. DNA input and approximate cells input
*indicates CSF sample was at diagnosis. ◌ No sample available; NA = not applicable
Supplementary table 2. Detailed clone information across compartments
Diagnosis BM BM relapse CSF relapse
CNS001 IGHV4-34*01/IGHD2-2*01/IGHJ5*02 85%
IGHV6-1*01/IGHJ5 *02 4%
IGHV4-34*01/IGHD2-2*01/IGHJ5*02 0.002%
IGHV6-1*01/IGHJ5 *02 88%
IGHV4-34*01/IGHD2-2*01/IGHJ5*02 0
IGHV6-1*01/IGHJ5 *02 78%
CNS002 IGHV1-69*06/IGHD5-12*01/IGHJ4*02 36%
IGHV3-72*01/IGHD2-8*02/IGHJ4*02 11%
IGHV1-18*01/IGHD2-2*02/IGHJ6*02 10%
IGHV3-74*01/ IGHD4-23*01/IGHJ6*02 3%
IGHV3-74*01/IGHD5-12*01/IGHJ4*02 0.1%
IGHV3-74*01/IGHD7-27*01/IGHJ6*02 0
IGHV3-74*01/IGHJ6*02 0
IGHV1-69*06/IGHD5-12*01/IGHJ4*02 45%
IGHV3-72*01/IGHD2-8*02/IGHJ4*02 0
IGHV1-18*01/IGHD2-2*02/IGHJ6*02 0
IGHV3-74*01/ IGHD4-23*01/IGHJ6*02 0
IGHV3-74*01/IGHD5-12*01/IGHJ4*02 34%
IGHV3-74*01/IGHD7-27*01/IGHJ6*02 0.6%
IGHV3-74*01/IGHJ6*02 0.06%
IGHV1-69*06/IGHD5-12*01/IGHJ4*02 5%
IGHV3-72*01/IGHD2-8*02/IGHJ4*02 0
IGHV1-18*01/IGHD2-2*02/IGHJ6*02 0
IGHV3-74*01/ IGHD4-23*01/IGHJ6*02 0
IGHV3-74*01/IGHD5-12*01/IGHJ4*02 0.1%
IGHV3-74*01/IGHD7-27*01/IGHJ6*02 43%
IGHV3-74*01/IGHJ6*02 14%
CNS003 IGHV1-46*01/IGHD3-3*01/IGHJ4*02 91% IGHV1-46*01/IGHD3-3*01/IGHJ4*02 50% IGHV1-46*01/IGHD3-3*01/IGHJ4*02 94%
CNS004 IGHV4-34*01/IGHD3-16*01/IGHJ2*01 40%
IGHV6-1*01/IGHD3-9*01/IGHJ4*01 16%
NA IGHV4-34*01/IGHD3-16*01/IGHJ2*01 22%
IGHV6-1*01/IGHD3-9*01/IGHJ4*01 41%
CNS005 IGHV1-8*01/ IGHD2-2*02/IGHJ6 *03 55%
IGHV3-23/ IGHD2-2*02/IGHJ6 *03 0.005%
IGHV1-2*04/ IGHD3-22*01/IGHJ6*03 0.01%
IGHV1-8*01/ IGHD2-2*02/IGHJ6 *03 †v-v replaced
IGHV3-23/ IGHD2-2*02/IGHJ6 *03 40%
IGHV1-2*04/ IGHD3-22*01/IGHJ6*03 48%
IGHV1-8*01/ IGHD2-2*02/IGHJ6 *03 †v-v replaced
IGHV3-23/ IGHD2-2*02/IGHJ6 *03 39%
IGHV1-2*04/ IGHD3-22*01/IGHJ6*03 45%
CNS006 IGHV6-1*01/IGHD3-10*01/IGHJ6*02 26%
IGHV3-30-3*01/IGHJ4*02 2%
IGHV3-11*06/IGHJ4*02 0
IGHV1-3*01/IGHD2-8*01/IGHJ4*02 2%
IGHV3-30-3*01/IGHD2-8*01/IGHJ4*02 2%
IGHV3-23*01/IGHD2-8*01/IGHJ4*02 0
IGHV6-1*01/ IGHD2-8*01/IGHJ4*02 0.4%
IGHV3-30*18/IGHJ4*02 0.01%
IGHV7-4-1*01/IGHJ6*02 0.02%
IGHV6-1*01/IGHD3-10*01/IGHJ6*02 0.9%
IGHV3-30-3*01/IGHJ4*02 10%
IGHV3-11*06/IGHJ4*02 41%
IGHV1-3*01/IGHD2-8*01/IGHJ4*02 11%
IGHV3-30-3*01/IGHD2-8*01/IGHJ4*02 10%
IGHV3-23*01/IGHD2-8*01/IGHJ4*02 7%
IGHV6-1*01/ IGHD2-8*01/IGHJ4*02 0.5%
IGHV3-30*18/IGHJ4*02 0.7%
IGHV7-4-1*01/IGHJ6*02 0.1%
IGHV6-1*01/IGHD3-10*01/IGHJ6*02 0
IGHV3-30-3*01/IGHJ4*02 1%
IGHV3-11*06/IGHJ4*02 0
IGHV1-3*01/IGHD2-8*01/IGHJ4*02 1%
IGHV3-30-3*01/IGHD2-8*01/IGHJ4*02 1%
IGHV3-23*01/IGHD2-8*01/IGHJ4*02 0
IGHV6-1*01/ IGHD2-8*01/IGHJ4*02 26%
IGHV3-30*18/IGHJ4*02 21%
IGHV7-4-1*01/IGHJ6*02 16%
CNS007 NA IGHD6-13*01/IGHJ4*02 37%
IGHD2-2*02/IGHJ6*02 15%
IGHD2-2*02/IGHJ4*02 0
IGHD6-13*01/IGHJ4*02 45%
IGHD2-2*02/IGHJ4*02 0
IGHD2-2*02/IGHJ4*02 11%
CNS008 NA IGHV3-30-3*01/IGHD3-9*01/IGHJ6*03 95% IGHV3-30-3*01/IGHD3-9*01/IGHJ6*03 64%
CNS009 NA IGHV1-46*01/IGHD5-12*01/IGHJ4*02 34%
IGHV3-71*02/ IGHD6-6*01/IGHJ4*02 31%
IGHV1-46*01/IGHD5-12*01/IGHJ4*02 48%
IGHV3-71*02/ IGHD6-6*01/IGHJ4*02 40%
CNS010 IGHV3-15*01/IGHD6-19*01/IGHJ6*02 31%
IGHV4-59*01/ IGHD3-10*01/IGHJH3*02 24%
IGHV3-33*01/ IGHD6-6*01/IGHJ2*01 12%
IGHV1-46*01/ IGHJ4*02 6%
IGHV4-34*01/ IGHJ2*01 0.0001%
IGHV3-15*01/IGHD6-19*01/IGHJ6*02 0.05%
IGHV4-59*01/ IGHD3-10*01/IGHJH3*02 0
IGHV3-33*01/ IGHD6-6*01/IGHJ2*01 0
IGHV1-46*01/ IGHJ4*02 0
IGHV4-34*01/ IGHJ2*01 0.12%
IGHV3-15*01/IGHD6-19*01/IGHJ6*02 41%
IGHV4-59*01/ IGHD3-10*01/IGHJH3*02 0
IGHV3-33*01/ IGHD6-6*01/IGHJ2*01 0
IGHV1-46*01/ IGHJ4*02 0
IGHV4-34*01/ IGHJ2*01 46%
CNS011 NA IGHV4-34/ IGHD3-9*01 /IGHJ6*02 0.54%
IGHV3-33*01/IGHD3-10*02/IGHJ3*02 0.33%
IGHV4-34/ IGHD3-9*01 /IGHJ6*02 54%
IGHV3-33*01/IGHD3-10*02/IGHJ3*02 34%
CNS012 IGHV1-2*04/ IGHD7-27*01/ IGHJ2*01 32.4%
IGHV7-4-1*02/ IGHD5-12*01/ IGHJ6*02 31.7%
IGHV1-2*04/ IGHD7-27*01/ IGHJ2*01 0.58%
IGHV7-4-1*02/ IGHD5-12*01/ IGHJ6*02 0.01%
IGHV1-2*04/ IGHD7-27*01/ IGHJ2*01 54%
IGHV7-4-1*02/ IGHD5-12*01/ IGHJ6*02 35.2%
NA = sample not available; †Patient CNS005: The dominant clone in the diagnostic BM IGHV1-8*01/ IGHD2-2*02/IGHJ6 *03 (55%) is not detectable at
relapse, but on further analysis this has been V-V replaced (Supplementary figure 2), where by IGHV1-8*01 is replaced to creating the IGHV3-23/ IGHD2-
2*02/IGHJ6 *03 clone at relapse (40% and 39% in BM and CNS respectively). The v-v replaced clone is detected at low level (0.005%) in the diagnostic BM,
indicating the presence of clonal evolution at diagnosis.
IGHD7-27*01
Clone 1 43% AAATGAACAGTCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCAAGAGCCCCTGGGGACTACTACGGTATGGACGTCTGGGGCCAAG
||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||||
Clone 2 14% AAATGAACAGTCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCAAGAGACTTCTACTACTACTACGGTATGGACGTCTGGGGCCAAG
IGHJ6*02 ATTA4CTACTACTACTACGGTATGGACGTCTGGGGCCAAG
IGHV3-74*01 CACGGCTGTGTATTACTGTGCAAGAGA
Supplementary Figure 1. Analysis of clones in CSF sample CNS002. The dominant
clones in the CSF (clone 1 74*01/IGHD7-27*01/IGHJ6*02 and clone 2 IGHV3-
74*01/IGHJ6*02) share the same IGHV and IGHJ gene usage but the CDR3 regions are
different and unrelated.
AGATCTGAGGACACGGCCGTGTATTACTGTGCGAGAGG IGHV1-8*01
IGHV1-8*01/IGHD2-2*02/IGHJ6*03 AGATCTGAGGACACGGCCGTGTATTACTGTGCGAGAGCCACAGGAATATTGTAGTAGTACCAGCTGCTATAGAGGGCTACTACTACTACTACATGGACGTCTGGGGCAAAGGGACCACGGTCACC
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
IGHV3-23*01/IGHD2-2*02/IGHJ6*03 GAGGACACGGCCGTATATTACTGTGCTTAAAGACCCCTGATGGTGTTGTAGTAGTACCAGCTGCTATAGAGGGCTACTACTACTACTACATGGACGTCTGGGGCAAAGGGACCACGGTCACC
AGGATATTGTAGTAGTACCAGCTGCTATACC IGHD2-2*02
ATTACTACTACTACTACTACATGGACGTCTGGGGCAAAGGG IGHJ6*03
GAGGACACGGCCGTATATTACTGTGCGAAAGA IGHV3-23*01
Supplementary Figure 2. V-V replacement in CNS005. The dominant clone in the diagnostic BM IGHV1-8*01/IGHD2-2*02/IGHJ6*03 55% is
not detectable at relapse, but on further analysis this has been V-V replaced whereby IGHV1-8*01 is replaced to create the IGHV3-23/IGHD2-
2*02/IGHJ6*03 clone at relapse
